to refuse traditional use registration on safety grounds and the reasons behind this decision . Article 16f 1. The Committee referred to in Article 16h shall set up a classification of herbal medicinal products, taking into account their composition and their pharmacological and toxicological effects. Within this classification, the Committee shall indicate for each herbal medicinal product therapeutic indications, route(s) of administration, daily doses, possible adverse reactions and any risk of interactions with drugs, alcohol and foods; it shall also provide any other information required for their safe use, especially by children, pregnant women and elderly people. 2. If an application for traditional use registration relates to a herbal substance contained in the list referred to in paragraph 1, the data specified in Article 16c(1) , points (b), (c) and (d) does not need to be provided. Article 16e(1), points (c) and (d) shall not apply. 3. If a herbal substance ceases to be included in the list referred to in paragraph 1, registrations pursuant to paragraph 2 for herbal medicinal products containing this substance shall be revoked unless the particulars and documents referred to in Article 16c(1) are submitted within three months. Article 16g 1. Articles 3(1) and (2), 4(4), 12, 17(1), 19, 20, 23, 24, 25, 40 to 52, 70 to 85, 101 to 108, 111(1) and (3), 112, 116 to 118, 122, 123, 125, 126 second indent, 127 of this Directive, as well as Directive 91/356/EEC* shall apply, by analogy, to traditional use registration granted under this chapter. 2. In addition to the provisions laid down in Articles 54 to 65, any labelling and user package leaflet shall contain a statement to the effect that: a) the product is a herbal medicinal product for traditional use in a specified indication and that the efficacy of the product relies exclusively on long-term use and experience ; b) the user should consult a doctor or a qualified practitioner if the symptoms persist during the use of the medicinal product or if adverse reactions occur; and c) the product may have side effects, or toxic effects, and that there is a risk of dangerous interaction with foods and/or drugs taken concomitantly. A Member State may provide that the labelling and the user package leaflet shall also state the nature of the tradition in question. 3. In addition to the provisions laid down in Articles 86 to 99, any advertisement for